Bajaj HealthCare Limited BAJAJHCARE NSEPHARMA
Company Overview
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anthelmintic, anti viral, anti coagulant, vitamin c, anti arthritis, atypical antipsychotic agent, anti convulsant, vasoprotective, disinfectant, anti asthamatic, neuro protective, anti histamine, iron chelator, vasoprotective, urinary tract infection, anti migraine, anti rheumatic, antibiotic, anti tussive, weight reducing, hemorheologic agent, vasodilator, anti psychotic, beta agonist, gastroretentive drug, and antagonist. It also provides 2-amino-3,5-dibromobenzaldehyde, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid and octopamine HCL, 8- chloro theophylline, chlorohexanone, theobromine, hesperidin, 5-amino-2,4,6-triiodoisophthaloyl dichloride, 3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8- bromo xanthine, 8 bromo-3-methyl xanthine, 4,5-dinitroaniline, 4,5-dichloro-2-nitroaniline, and 2-amino -4- hydroxyacetophenone. In addition, it offers nutraceuticals; and formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹611.03 Cr (+12.6% YoY); net profit ₹15.77 Cr.
- Trailing 12 Months Year-on-year growth — revenue +11.3%, earnings +11.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.8%, profit CAGR -28.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.83% |
| 1 Year: | 11.30% |
Compounded Profit Growth
| 5 Years: | -28.44% |
| 1 Year: | 11.50% |
Stock Price Performance
| 1 Year: | -29.72% |
| 6 Months: | -1.71% |
| 3 Months: | +2.65% |
| 1 Month: | -3.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.84 · Neutral
P/E of 46.85 is above the sector median of 35.90 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -1.8% CAGR over 5 years.
- Earnings shrank at -28.4% CAGR over 5 years.
- Trading 35.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BAJAJHCARE Bajaj HealthCare Limited NSEPHARMA | 324.65 | 46.85 | ₹1,092.94 Cr | 0.48% | 8.66% | 2.96% | -1.83% | -28.44% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 122.79 Cr | 154.47 Cr | 148.84 Cr | 161.22 Cr | 153.06 Cr | 165.63 Cr |
| Cost of Revenue | 60.91 Cr | 93.97 Cr | 80.59 Cr | 80.70 Cr | 81.51 Cr | 86.10 Cr |
| Gross Profit | 61.88 Cr | 60.50 Cr | 68.25 Cr | 80.53 Cr | 71.55 Cr | 79.53 Cr |
| Operating Expenses | 47.09 Cr | 56.28 Cr | 49.38 Cr | 57.05 Cr | 56.50 Cr | 57.80 Cr |
| Operating Income | 14.79 Cr | 4.23 Cr | 18.87 Cr | 23.48 Cr | 15.05 Cr | 21.74 Cr |
| EBITDA | 24.01 Cr | 25.33 Cr | 25.39 Cr | 32.33 Cr | -7.61 Cr | 29.56 Cr |
| Interest Expense | 5.51 Cr | 6.08 Cr | 5.23 Cr | 5.88 Cr | 5.57 Cr | 6.09 Cr |
| Pretax Income | 11.65 Cr | 11.72 Cr | 14.53 Cr | 19.24 Cr | -20.81 Cr | 16.46 Cr |
| Tax Provision | -3.31 Cr | 12.90 L | 2.35 Cr | 3.14 Cr | -1.40 Cr | 2.57 Cr |
| Net Income | 11.72 Cr | 11.18 Cr | 11.83 Cr | 15.67 Cr | -22.85 Cr | 13.70 Cr |
| Diluted EPS | 3.64 | 3.46 | 3.64 | 4.87 | -7.16 | 4.06 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 645.80 Cr | 472.93 Cr | 542.60 Cr | 611.03 Cr |
| Cost of Revenue | - | 386.88 Cr | 259.13 Cr | 286.45 Cr | 316.39 Cr |
| Gross Profit | - | 258.91 Cr | 213.80 Cr | 256.16 Cr | 294.64 Cr |
| Operating Expenses | - | 164.61 Cr | 165.09 Cr | 201.65 Cr | 217.37 Cr |
| Operating Income | - | 94.31 Cr | 48.71 Cr | 54.51 Cr | 77.27 Cr |
| EBITDA | - | 121.94 Cr | 43.83 Cr | 101.83 Cr | 78.71 Cr |
| Interest Expense | - | 16.40 Cr | 29.05 Cr | 27.90 Cr | 22.23 Cr |
| Pretax Income | - | 78.18 Cr | -16.68 Cr | 46.01 Cr | 28.92 Cr |
| Tax Provision | - | 14.65 Cr | -2.35 Cr | 3.08 Cr | 7.61 Cr |
| Net Income | - | 43.02 Cr | -83.79 Cr | 39.50 Cr | 15.77 Cr |
| Diluted EPS | - | 15.59 | -30.36 | 13.12 | 4.98 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 897.66 Cr | 765.13 Cr | 833.05 Cr | 923.22 Cr |
| Current Assets | - | 500.40 Cr | 480.05 Cr | 560.91 Cr | 639.01 Cr |
| Cash & Equivalents | - | 17.72 Cr | 2.17 Cr | 2.60 Cr | 37.24 Cr |
| Inventory | - | 208.79 Cr | 144.04 Cr | 161.89 Cr | 216.01 Cr |
| Receivables | - | 194.17 Cr | 180.24 Cr | 251.67 Cr | 233.85 Cr |
| Total Liabilities | - | 529.97 Cr | 486.77 Cr | 366.88 Cr | 390.21 Cr |
| Current Liabilities | - | 433.60 Cr | 441.48 Cr | 296.98 Cr | 332.48 Cr |
| Long Term Debt | - | 93.66 Cr | 38.58 Cr | 64.67 Cr | 47.57 Cr |
| Total Debt | - | 415.24 Cr | 332.82 Cr | 223.25 Cr | 249.09 Cr |
| Total Equity | - | 367.69 Cr | 278.36 Cr | 466.16 Cr | 533.00 Cr |
| Shares Outstanding | - | 2.76 Cr | 2.76 Cr | 3.16 Cr | 3.37 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -22.19 Cr | 92.29 Cr | 21.62 Cr | 58.08 Cr |
| Investing Cash Flow | - | -93.43 Cr | -11.24 Cr | -14.82 Cr | -47.78 Cr |
| Financing Cash Flow | - | 131.37 Cr | -96.60 Cr | -6.38 Cr | 24.33 Cr |
| Capital Expenditure | - | -93.59 Cr | -30.29 Cr | -11.54 Cr | -43.35 Cr |
| Free Cash Flow | - | -115.79 Cr | 62.01 Cr | 10.08 Cr | 14.73 Cr |
| Net Change in Cash | - | 15.75 Cr | -15.55 Cr | 42.91 L | 34.63 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 40.1% | 45.2% | 47.2% | 48.2% |
| Operating Margin % | - | 14.6% | 10.3% | 10.0% | 12.6% |
| Net Margin % | - | 6.7% | -17.7% | 7.3% | 2.6% |
| ROE % | - | 11.7% | -30.1% | 8.5% | 3.0% |
| ROCE % | - | 20.3% | 15.1% | 10.2% | 13.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BAJAJHCARE
Some Shareholders Feeling Restless Over Bajaj HealthCare Limited's (NSE:BAJAJHCARE) P/S Ratio - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOYjBqRDMtdHR3T1JfN1ZEcVpvVW1EOHBWLVRBdm1hLTN1ZlJOYWJiTlNTVUNxdDZ5QzY1cWtXZ05Mcy1lRk5PWDJJbGxUMmI1NmhNd0k4b1Jqa0tEYkUyTWdFbnRaSE5sdUhQZ2M1SFI5VkVlSWZXSy1DYmxFV1FTWENVQW95REI1ZmZoV2…
BAJAJHCARE Stock Price and Chart — NSE:BAJAJHCARE - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1EQ2g0VlVCbnE1YUU4VWZ3SHFMczVtVzJYM1VzelBoc0N2YlQ3bU90TGJOWmR5WHhBRFpXRUVkOF94cmo5MzVyczktOWRjaEhIU2xpZ0l6Q0FuUUE5QzBYdw?oc=5" target="_blank">BAJAJHCARE Stock Price and Chart — NS…
Bajaj Healthcare Co-Promoter acquires 100,000 shares via open market to strengthen stake. - Sahi
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPcE0xZ2UtcHp6WnpNQUlibTFHQ2piVXh4UmljZkJnSm93aHVVSDNIZ3JqRUpiUlNaWnpHNjZZVXRvYUpveVpvYjJoYkxrTU9TVUlGZzNpYjdpMFlDWkNBVDhxR0hsaEh2eFpsek9BTUs0MlkxZkJzdWl3eGQ1ekZpWFlWWWkyWHMtZlc3bU…
Bajaj Healthcare (NSE:BAJAJHCARE): What Is the Record Date for Its FY26 Final Dividend? - Kalkine India
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOZ3pzbDJvLWdMbTZ4bEJTcVh0YWFNTUxKNENORFVBNEhhWURtdjRsZXdieU40YzJ3cnR3ME5KQzZiWE00VU9LN1gxLXg3UzVkaWJhTjRZLWtoNlIyTm9hUE1NSjR6ZUhTYjRrVG05MFY2eU01UU52SGlCUXRuelI1LVhmZlYzdG9yVUtuWE…
Bajaj Healthcare Ltd Q1 FY27 Results Preview - Univest
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1icEsyTVp1QjNmaTVCdWpSNzMzQjlFQl9GNWNWWDF5UUJuMWpyZWhTUlgwbkVKdUltR242OElrcl9sNGdIRm1LZzNZbzlZWG1XRGxhQ1ROQmFHRFNRUEktQ0FwS0RDX3JFRllzaHFB?oc=5" target="_blank">Bajaj Healthcare Lt…
Bajaj Healthcare BAJAJHCARE Trading Window Closure October 2026 - Kalkine India
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNSEtlb3R6anVPVjI4NzZteWpNcVR2T3VxV1VXZ09GWlBUQktlcTFLLVo1TG9nUHg3RVBkdEljMjhQcW81d2JfZ2ZtdHgxU2hYRFNWcVYwQzcydGVzNmRaYU5pLVVYT2hvNHJqVlVRWldZSzVzN1FrV1JETFh5dEZLcXcwRU9VcnhMUDhuZG…
BAJAJHCARE — Frequently Asked Questions
What is the current share price of Bajaj HealthCare Limited (BAJAJHCARE)?
As of 2026-10-24 04:55 IST, Bajaj HealthCare Limited (BAJAJHCARE) trades at ₹324.65 on NSE. Its 52-week range is ₹273.71 to ₹504.97.
What is the market capitalisation of BAJAJHCARE?
Bajaj HealthCare Limited (BAJAJHCARE) has a market capitalisation of ₹1,092.94 Cr on NSE.
What is the P/E ratio of BAJAJHCARE?
BAJAJHCARE trades at a trailing price-to-earnings (P/E) ratio of 46.85. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 1.92.
Does BAJAJHCARE pay a dividend?
Bajaj HealthCare Limited (BAJAJHCARE) currently offers a dividend yield of 0.48%.
What is the return on equity (ROE) of BAJAJHCARE?
BAJAJHCARE has a return on equity (ROE) of 2.96%. Its return on capital employed (ROCE) is 8.66%.
Is BAJAJHCARE a good stock to buy?
This page provides a data-driven analysis of Bajaj HealthCare Limited (BAJAJHCARE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.